Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
about
Modulation of Autophagy by Sorafenib: Effects on Treatment ResponseEvaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugsTargeting the VEGF pathway in metastatic bladder cancer.Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.Epigenetic Treatment Options in Urothelial Carcinoma.[Resistance to anti-angiogenic therapy: a clinical and scientific current issue].Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
P2860
Q26745320-19B698ED-F015-40F6-AB08-050D7E38D40BQ30489412-E8987766-1BB7-4DE2-9BFC-A2F817608AFDQ35998718-7FB40AD8-478F-4129-A3E6-FF74F45B91F2Q36413738-51D4C642-1FE7-41D8-AFCF-4E3962D5B9C0Q38534167-92B3EACB-A4CA-4D9C-8BEA-3CB64D0EBF2CQ38672966-E7A498FC-D8DA-4C90-A611-ADA346A192BFQ47212126-91413AF0-8121-4186-83D6-E28F9CAB495DQ50182584-2A9A1939-889C-43CA-BCCD-3CDD9266EC8CQ53787748-7FDF7A36-73A5-48DF-A181-CA61B0DC4F6CQ55254546-7F761AEA-D450-4683-B8E5-2A3C2D5EF1E2
P2860
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@ast
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@en
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@nl
type
label
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@ast
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@en
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@nl
prefLabel
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@ast
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@en
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@nl
P2093
P2860
P50
P356
P1476
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
@en
P2093
Annemarie Greife
Christiane Hader
Ingo Schmitz
Peter Albers
Tobias Lübke
P2860
P304
20500-20517
P356
10.3390/IJMS151120500
P407
P577
2014-11-07T00:00:00Z